Business
BostonGene and AstraZeneca Announce Strategic Collaboration to Advance Foundation Model-Driven Oncology Development
WALTHAM, Mass., January 06, 2026--BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with AstraZeneca, a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, to advance oncology drug development using BostonGene’s multimodal AI platform.
About this update from Astrazeneca Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/fc6cdc3826878f903c8c31fecc1bf40e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xOqjR68mmkdMWM3slNz_Vw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/fc6cdc3826878f903c8c31fecc1bf40e","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/EMO21yj5m6IPuURYdnkDWg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/fc6cdc3826878f903c8c31fecc1bf40e","width":1024,"height":512}},"lazy":false},{"type":"text","content":"AI-powered platform to predict patient safety and efficacy profiles, unlocking precision-driven oncology development","length":116,"tagName":"p","attribs":{}},{"type":"text","content":"WALTHAM, Mass., January 06, 2026--(BUSINESS WIRE)--BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with AstraZeneca, a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, to advance oncology drug development using BostonGene’s multimodal AI platform.","length":471,"tagName":"p"},{"type":"text","content":"The collaboration leverages BostonGene’s foundation model for tumor and immune biology to deliver predictive insights on patient-level safety and efficacy outcomes in early clinical trials. AstraZeneca will apply BostonGene’s omnimodal analytics to accelerate development timelines and reducing risk across its oncology portfolio.","length":330,"tagName":"p"},{"type":"text","content":""BostonGene’s platform combines deep biological insights with advanced AI and this collaboration will empower us to predict which patients will benefit from treatment helping us design safer, more effective therapies from the start," said Jorge Reis-Filho, MD, PhD, Chief of AI for Science Innovation, Enterprise AI Unit, AstraZeneca. "At AstraZeneca, we are focused on leveraging the vast and unparalleled potential of AI to accelerate clinical development and the delivery of innovative medicines to patients.&q...